CA2997015A1 - Antibodies that specifically bind to tl1a - Google Patents

Antibodies that specifically bind to tl1a Download PDF

Info

Publication number
CA2997015A1
CA2997015A1 CA2997015A CA2997015A CA2997015A1 CA 2997015 A1 CA2997015 A1 CA 2997015A1 CA 2997015 A CA2997015 A CA 2997015A CA 2997015 A CA2997015 A CA 2997015A CA 2997015 A1 CA2997015 A1 CA 2997015A1
Authority
CA
Canada
Prior art keywords
seq
acid sequence
amino acid
antibody according
recombinant antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2997015A
Other languages
English (en)
French (fr)
Inventor
Lynn Dorothy Poulton
Matthew Pollard
Anthony G. Doyle
Bridget Ann Cooksey
Vanya PANDE
Adam William Clarke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon LLC filed Critical Cephalon LLC
Publication of CA2997015A1 publication Critical patent/CA2997015A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Sorting Of Articles (AREA)
CA2997015A 2015-09-18 2016-09-16 Antibodies that specifically bind to tl1a Pending CA2997015A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562220442P 2015-09-18 2015-09-18
US62/220,442 2015-09-18
PCT/US2016/052040 WO2017049024A1 (en) 2015-09-18 2016-09-16 Antibodies that specifically bind to tl1a

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3306751A Division CA3306751A1 (en) 2015-09-18 2016-09-16 Antibodies That Specifically Bind to TL1A

Publications (1)

Publication Number Publication Date
CA2997015A1 true CA2997015A1 (en) 2017-03-23

Family

ID=57043002

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2997015A Pending CA2997015A1 (en) 2015-09-18 2016-09-16 Antibodies that specifically bind to tl1a

Country Status (33)

Country Link
US (4) US10138296B2 (enExample)
EP (2) EP3350223B1 (enExample)
JP (2) JP7013366B2 (enExample)
KR (1) KR101998535B1 (enExample)
CN (1) CN108137693B (enExample)
AR (1) AR106055A1 (enExample)
AU (2) AU2016323460B2 (enExample)
BR (1) BR122021002400A8 (enExample)
CA (1) CA2997015A1 (enExample)
CL (1) CL2018000711A1 (enExample)
CO (1) CO2018003736A2 (enExample)
CY (1) CY1123499T1 (enExample)
DK (1) DK3350223T3 (enExample)
EA (1) EA201890756A1 (enExample)
ES (1) ES2810751T3 (enExample)
HR (1) HRP20201323T1 (enExample)
HU (1) HUE051496T2 (enExample)
IL (1) IL257761B2 (enExample)
LT (1) LT3350223T (enExample)
MA (2) MA42825B1 (enExample)
MD (1) MD3350223T2 (enExample)
MX (1) MX2018003185A (enExample)
PE (1) PE20181080A1 (enExample)
PH (1) PH12018500580B1 (enExample)
PL (1) PL3350223T3 (enExample)
PT (1) PT3350223T (enExample)
RS (1) RS60703B1 (enExample)
SI (1) SI3350223T1 (enExample)
SM (1) SMT202000500T1 (enExample)
TW (1) TWI703158B (enExample)
UA (1) UA125284C2 (enExample)
WO (1) WO2017049024A1 (enExample)
ZA (1) ZA201801427B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
MX2014003689A (es) 2011-09-30 2014-12-05 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos contra tl1a y sus usos.
KR20230109779A (ko) 2013-03-27 2023-07-20 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전
EP4105236A1 (en) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
WO2017096358A1 (en) * 2015-12-04 2017-06-08 University Of Iowa Research Foundation Apparatus, systems and methods for predicting, screening and monitoring of encephalopathy / delirium
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
KR20180127416A (ko) 2016-03-17 2018-11-28 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
CN118240830A (zh) 2016-10-26 2024-06-25 西达-赛奈医疗中心 中和抗tl1a单克隆抗体
ES3066090T3 (en) * 2017-04-28 2026-05-11 Ajinomoto Co Inc Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof
CN112585165B8 (zh) 2018-04-25 2025-02-14 普罗米修斯生物科学公司 优化的抗tl1a抗体
CN114375339A (zh) 2019-05-14 2022-04-19 普罗米修斯生物科学公司 Tl1a患者选择方法、系统和装置
CN114901311A (zh) 2019-10-24 2022-08-12 普罗米修斯生物科学公司 Tnf样配体1a（tl1a）的人源化抗体及其用途
KR20230051581A (ko) * 2020-08-19 2023-04-18 얀센 바이오테크 인코포레이티드 조작된 리간드를 사용하는 물질 및 방법
WO2022178158A1 (en) * 2021-02-18 2022-08-25 Prometheus Biosciences, Inc. Anti-tl1a antibody compositions and methods of treatment in the lung
IL318297A (en) 2022-07-27 2025-03-01 Cephalon Llc Anti-TL1A antibody formulations
CA3262839A1 (en) 2022-07-27 2024-02-01 Cephalon Llc ANTI-TL1A ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS AND CROHN'S DISEASE
IL324671A (en) 2023-05-17 2026-01-01 Genentech Inc Anti-tl1a antibody therapeutic methods
WO2024263868A2 (en) * 2023-06-21 2024-12-26 Paragon Therapeutics, Inc. Tl1a antibody compositions and methods of use
WO2024263900A2 (en) * 2023-06-22 2024-12-26 Paragon Therapeutics, Inc. Il-23 antibody compositions and methods of use
WO2024263945A2 (en) * 2023-06-22 2024-12-26 Paragon Therapeutics, Inc. Il-17 antibody compositions and methods of use
IL325993A (en) 2023-08-11 2026-03-01 Paragon Therapeutics Inc TL1A binding proteins and methods of use
US12473370B2 (en) 2023-10-03 2025-11-18 Absci Corporation TL1A associated antibody compositions and methods of use
CN120058933B (zh) * 2023-11-30 2026-02-10 北京智仁美博生物科技有限公司 抗肿瘤坏死因子样配体1a的抗体及其用途
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods
CN120424214A (zh) * 2024-02-05 2025-08-05 三生国健药业（上海）股份有限公司 一种抗tl1a抗体及其制备方法和用途
WO2025170982A2 (en) 2024-02-06 2025-08-14 Paragon Therapeutics, Inc. Il-23 antibody compositions and methods of use
CN120590530A (zh) * 2024-03-05 2025-09-05 帆礼生物技术(武汉)有限公司 靶向tl1a的抗体及其应用
US20250376530A1 (en) 2024-05-17 2025-12-11 Genentech, Inc. Methods for treatment of inflammatory bowel disease with an anti-tl1a antibody
WO2026072993A1 (en) 2024-09-27 2026-04-02 Genentech, Inc. Methods for treatment of metabolic dysfunction-associated steatohepatitis with an anti-tl1a antibody
WO2026072983A1 (en) 2024-09-27 2026-04-02 Genentech, Inc. Methods for treatment of atopic dermatitis with an anti-tl1a antibody
CN119552252B (zh) * 2025-01-16 2025-11-25 华润生物医药有限公司 抗tl1a抗体及其制备方法和应用

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820798B2 (en) 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6548062B2 (en) * 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20040191243A1 (en) 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
CA2536086C (en) 2003-08-20 2013-03-19 University Of Miami Inhibition of dr3 in the treatment of allergic lung inflammation
BRPI0509201A (pt) 2004-03-23 2007-08-28 Biogen Idec Inc agentes de acoplamento de receptor e usos terapêuticos destes
GB0521621D0 (en) * 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
WO2006127900A2 (en) 2005-05-25 2006-11-30 Biogen Idec Ma Inc. Tl1a in the treatment of disease
BRPI0617057A2 (pt) 2005-08-30 2011-07-12 Univ Miami anticorpo isolado, toxina especìfica para receptor de fator de necrose tumoral 25 (tnfr25), método para ativar o receptor de fator de necrose tumoral 25 (tnfr25), método para inibir a sinalização do receptor de fator de necrose tumoral 25 (tnfr25) numa célula, vacina antitumoral, método para imunizar um paciente contra tumor, método para tratar cáncer num paciente, método para tratar e/ou prevenir inflamação intestinal, composição terapêutica para a facilitação de um transplante de órgão, método para transplantar um tecido de um doador para um hospedeiro, método para inibir a expressão clonal de uma população de células t cd8 cognatas, método para tratar e/ou prevenir inflamação pulmonar, antagonista de tnfr25 isolado, composição e vetor de expressão
WO2007076465A2 (en) 2005-12-23 2007-07-05 Diadexus, Inc. Cln248 antibody compositions and methods of use
US20110217310A1 (en) 2007-01-10 2011-09-08 Siegel Richard M Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology
US20100190162A1 (en) * 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2009052512A2 (en) 2007-10-19 2009-04-23 Cedars-Sinai Medical Center Methods of using genetic variants to diagnose and predict inflammatory bowel disease
MX2010005282A (es) 2007-11-13 2010-08-31 Teva Pharma Anticuerpos humanizados contra tl1a.
WO2010118210A1 (en) 2009-04-08 2010-10-14 Cedars-Sinai Medical Center Methods of predicting complication and surgery in crohn's disease
EP2519260A2 (en) 2009-12-31 2012-11-07 Deutsches Krebsforschungszentrum Novel modulators of trail signalling
JO3375B1 (ar) * 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
AU2012259312A1 (en) 2011-05-20 2013-12-12 Government Of The United States, As Represented By The Secretary Department Of Health And Human Services Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof
WO2012174338A2 (en) 2011-06-15 2012-12-20 Glaxosmithkline Llc Method of selecting therapeutic indications
MX2014003689A (es) * 2011-09-30 2014-12-05 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos contra tl1a y sus usos.
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
EA201591153A1 (ru) 2013-01-02 2016-01-29 Гленмарк Фармасьютикалс С.А. Антитела, связывающиеся с tl1a, и их применение
KR20230109779A (ko) 2013-03-27 2023-07-20 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전
HK1220919A1 (zh) * 2013-04-05 2017-05-19 F. Hoffmann-La Roche Ag 抗il-4抗体和双特异性抗体及其用途
CN105358713B (zh) 2013-05-17 2020-02-28 雪松-西奈医学中心 与克罗恩病相关的tnfsf15和dcr3的变体
EP2996717A4 (en) 2013-05-17 2016-11-23 Cedars Sinai Medical Center DIFFERENT EFFECTS OF IFN-GAMMA AND IL-17 ON TL1A-MODULATED INFLAMMATION AND FIBROSIS
EP4105236A1 (en) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
WO2015035261A1 (en) 2013-09-06 2015-03-12 Cedars-Sinai Medical Center Systems, devices and methods for anti-tl1a therapy
EP3068801A1 (en) * 2013-11-13 2016-09-21 Pfizer Inc. Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
US10519485B2 (en) 2015-04-15 2019-12-31 Biosearch Technologies, Inc. Dual quencher probes
US20180156781A1 (en) 2015-05-15 2018-06-07 Cedars-Sinai Medical Center Models, methods and compositions for treating inflammatory bowel disease
CA2994719A1 (en) 2015-08-21 2017-03-02 The Children's Hospital Of Philadelphia Methods of treating autoimmune conditions in patients with genetic variations in dcr3 or in a dcr3 network gene
TWI703158B (zh) * 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
US20180319889A1 (en) 2015-11-02 2018-11-08 La Jolla Institute For Allergy & Immunology Method and medicament for treating airway and/or lung diseases
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
KR20180127416A (ko) 2016-03-17 2018-11-28 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
US10968279B2 (en) 2016-05-09 2021-04-06 Bristol-Myers Squibb Company TL1A antibodies and uses thereof
GB201608323D0 (en) 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
MX389320B (es) 2016-06-09 2025-03-20 Pelican Therapeutics Inc Anticuerpos anti-tnfrsf25
CN118240830A (zh) 2016-10-26 2024-06-25 西达-赛奈医疗中心 中和抗tl1a单克隆抗体
US10626180B2 (en) 2017-04-20 2020-04-21 Cedars-Sinai Medical Center Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease
CN112585165B8 (zh) 2018-04-25 2025-02-14 普罗米修斯生物科学公司 优化的抗tl1a抗体
MA52251A (fr) 2018-04-30 2021-02-17 Cedars Sinai Medical Center Procédés et systèmes de sélection et de traitement de patients souffrant de maladies inflammatoires
CA3121167A1 (en) 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Methods of stratifying and treating a sub-population of inflammatory bowel disease patients
CN114375339A (zh) 2019-05-14 2022-04-19 普罗米修斯生物科学公司 Tl1a患者选择方法、系统和装置
WO2021081365A1 (en) 2019-10-24 2021-04-29 Prometheus Biosciences, Inc. Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
WO2021108694A1 (en) 2019-11-27 2021-06-03 Cedars-Sinai Medical Center Predicting extraintestinal manifestations of inflammatory bowel disease
WO2021247548A1 (en) 2020-06-03 2021-12-09 Cedars-Sinai Medical Center Treatments for a sub-population of inflammatory bowel disease patients
WO2021247770A1 (en) 2020-06-03 2021-12-09 Cedars-Sinai Medical Center Methods and systems for measuring post-operative disease recurrence
CN116322762A (zh) 2020-06-26 2023-06-23 辉瑞公司 用tl1a抗体治疗炎症性肠病的方法
JP2023551602A (ja) 2020-11-13 2023-12-08 プロメテウス バイオサイエンシーズ，インク． Ｔｌ１ａを標的とする炎症性疾患の治療のための方法、システム、およびキット
EP4256086A4 (en) 2020-12-01 2025-01-15 Cedars-Sinai Medical Center METHODS AND SYSTEMS FOR STRATIFICATION OF PATIENTS WITH INFLAMMATORY DISEASES
WO2022140283A1 (en) 2020-12-21 2022-06-30 Cedars-Sinai Medical Center Tl1a therapy compositions and methods of treatment therewith
IL305312A (en) 2021-02-18 2023-10-01 Prometheus Biosciences Inc Compositions comprising human antibodies to TNF-like ligand 1A (TL1A) and uses thereof
WO2022178158A1 (en) 2021-02-18 2022-08-25 Prometheus Biosciences, Inc. Anti-tl1a antibody compositions and methods of treatment in the lung
WO2022232253A1 (en) 2021-04-28 2022-11-03 Cedars-Sinai Medical Center Patient selection methods and kits for therapies targeting tl1a
WO2023102071A1 (en) 2021-12-01 2023-06-08 Cedars-Sinai Medical Center Microbial metabolites on intestinal inflammation
WO2023102051A1 (en) 2021-12-01 2023-06-08 Cedars-Sinai Medical Center Intestinal mononuclear phagocytes as prognostic biomarker for crohn's disease
AR128226A1 (es) 2022-01-07 2024-04-10 Prometheus Biosciences Inc Métodos para tratar enfermedades inflamatorias con una combinación de inhibidores de tl1a e inhibidores de il23
US20240059799A1 (en) 2022-05-11 2024-02-22 Pfizer Inc. Anti-tl1a antibodies and methods of use thereof

Also Published As

Publication number Publication date
US20190106486A1 (en) 2019-04-11
PH12018500580B1 (en) 2023-01-11
AU2016323460B2 (en) 2023-06-15
LT3350223T (lt) 2020-10-26
HK1256300A1 (zh) 2019-09-20
JP7013366B2 (ja) 2022-02-15
TWI703158B (zh) 2020-09-01
US20220185902A1 (en) 2022-06-16
SMT202000500T1 (it) 2020-11-10
PH12018500580A1 (en) 2018-10-15
CL2018000711A1 (es) 2018-11-23
KR101998535B1 (ko) 2019-07-09
IL257761A (en) 2018-04-30
UA125284C2 (uk) 2022-02-16
CN108137693A (zh) 2018-06-08
MA52643A (fr) 2021-03-24
SI3350223T1 (sl) 2020-10-30
IL257761B2 (en) 2023-03-01
EA201890756A1 (ru) 2018-08-31
DK3350223T3 (da) 2020-08-24
US11220549B2 (en) 2022-01-11
US12162946B2 (en) 2024-12-10
CO2018003736A2 (es) 2018-07-10
RS60703B1 (sr) 2020-09-30
AU2023203440B2 (en) 2026-04-16
MX2018003185A (es) 2018-08-01
JP2018528773A (ja) 2018-10-04
TW201722990A (zh) 2017-07-01
ES2810751T3 (es) 2021-03-09
MD3350223T2 (ro) 2020-09-30
CN108137693B (zh) 2021-11-26
KR20180048712A (ko) 2018-05-10
HRP20201323T1 (hr) 2020-11-27
HK1251002A1 (en) 2019-01-18
AU2023203440A1 (en) 2023-06-29
BR122021002400A8 (pt) 2023-01-24
PL3350223T3 (pl) 2021-03-08
PE20181080A1 (es) 2018-07-05
PT3350223T (pt) 2020-08-05
EP3693393A1 (en) 2020-08-12
EP3350223A1 (en) 2018-07-25
US10138296B2 (en) 2018-11-27
WO2017049024A1 (en) 2017-03-23
EP3350223B1 (en) 2020-06-17
JP2022051771A (ja) 2022-04-01
ZA201801427B (en) 2019-06-26
IL257761B (en) 2022-11-01
MA42825B1 (fr) 2020-09-30
HUE051496T2 (hu) 2021-03-01
NZ740731A (en) 2024-07-26
BR112018005407A2 (en) 2018-10-09
BR122021002400A2 (enExample) 2018-10-09
US20250179202A1 (en) 2025-06-05
AR106055A1 (es) 2017-12-06
US20170081400A1 (en) 2017-03-23
AU2016323460A1 (en) 2018-03-29
JP7341259B2 (ja) 2023-09-08
CY1123499T1 (el) 2022-03-24
BR112018005407A8 (pt) 2023-01-24

Similar Documents

Publication Publication Date Title
AU2023203440B2 (en) Antibodies that specifically bind to TL1A
US12410247B2 (en) Polynucleotides encoding antibodies that specifically bind to human IL-15
JP6548696B2 (ja) ヒト抗ｉｌ−３３中和モノクローナル抗体
JP7064666B2 (ja) ＦｃγＲＩＩＡに特異的な結合分子及びその使用
TWI904217B (zh) 抗par-2抗體及其使用方法
ES2984636T3 (es) Anticuerpos anti-IL-5
JP6501650B2 (ja) ヒト抗ｉｌ−３３中和モノクローナル抗体
HK40035876A (en) Antibodies that specifically bind to tl1a
HK1251002B (en) Antibodies that specifically bind to tl1a
EA042971B1 (ru) Антитела, которые специфически связываются с tl1a
BR112018005407B1 (pt) Anticorpo recombinante, composição compreendendo o mesmo, célula de bactéria ou levedura transformada, polinucleotídeos, uso do referido anticorpo, e método in vidro para detectar tl1a em uma amostra
HK1256300B (zh) 特异性地结合至tl1a的抗体
BR122024020794A2 (pt) Anticorpos que se ligam especificamente à il-15 humana e seus usos, composição, método in vitro para detecção de il-15 ou um complexo de il-15 e receptor de il-15-alfa, polinucleotídeo, vetor e método de produção do dito anticorpo

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210915

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240807

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240912

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240912

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240912

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241230

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250328

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250328

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUEST RECEIVED

Effective date: 20250605

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250605

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R13-R104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250623

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250905

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250905

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251127

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251128

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P124 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT AFTER ALLOWANCE (AAA) RECEIVED

Effective date: 20260115

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-P126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT AFTER ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260116

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260116

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260116

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20260330

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20260402

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260402